A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Latest Information Update: 17 Mar 2025
At a glance
- Drugs Trastuzumab-deruxtecan (Primary) ; Trastuzumab emtansine
- Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms DESTINY-B03; DESTINY-Breast03
- Sponsors Daiichi Sankyo Company; Daiichi Sankyo Inc
Most Recent Events
- 02 Dec 2024 According to a Daiichi Sankyo Company media release, exploratory biomarker analysis from this study will be presented as a Spotlight Poster Session on Thursday, December 12, 7:00 - 8:30 am, at San Antonio Breast Cancer Symposium (#SABCS24).
- 01 Sep 2024 Results assessing subgroup analysis of enrolled in DESTINY-Breast03 (n=309 At data cutoff (July 25, 2022) were published in the Cancer Science.
- 01 Aug 2024 Results (At data cutoff, 20 November 2023) assessing updated efficacy and safety analyses published in the Nature Medicine.